Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05042531 | Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05343676 | Different Sonographic Modalities and PET-CT in Pediatric Lymphoma | unknown | — | 45 | Assiut UniversityOTHER | 0 | Apr 25, 2022 | clinicaltrials |
| NCT05340829 |
| Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia |
| unknown |
| Phase 1 |
| 18 |
| He HuangOTHER |
| 1 |
| Apr 22, 2022 |
| clinicaltrials |
| NCT05340985 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | unknown | Phase 4 | 54 | Tehran University of Medical SciencesOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05339204 | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission | unknown | N/A | 75 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04480125 | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | unknown | Phase 2 | 28 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05322733 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | unknown | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05333705 | Donor Immune Cell Therapy for Acute Myeloid Leukemia | unknown | Phase 1 | 15 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05286164 | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | unknown | Phase 2 | 30 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05331313 | The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma(MMSPORADGEN) | unknown | — | 1,000 | Hospices Civils de LyonOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05275036 | Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies(ASCEND-LYM) | unknown | — | 493 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05326984 | Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia | unknown | N/A | 20 | Hospital General de MexicoOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04082910 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05325801 | A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 9 | Zhejiang UniversityOTHER | 0 | Apr 13, 2022 | clinicaltrials |
| NCT04743388 | Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System | unknown | — | 600 | National and Kapodistrian University of AthensOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05320081 | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04246359 | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma(RIPPLE) | unknown | Phase 2 | 52 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT04491825 | Diagnostic Classifier for Cutaneous T-cell Lymphomas | unknown | — | 160 | Medical University of ViennaOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05309213 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 58 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Apr 4, 2022 | clinicaltrials |
| NCT02752243 | CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. | unknown | Phase 1 / Phase 2 | 32 | Peter BaderOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03646422 | AEDV Registry of Primary Cutaneous Lymphoma | unknown | — | 2,000 | Fundación Academia Española de DermatologíaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05191225 | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study | unknown | Phase 4 | 48 | Laida Cuevas PalomaresNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04381221 | Observational MyPal-Child Study on the ePRO-based Early Palliative Care Digital System in Paediatric Oncology Patients(MyPal4Kids) | unknown | — | 100 | Centre for Research and Technology HellasOTHER | 2 | Mar 29, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT05249894 | Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy(LAM-SEPSIS) | unknown | — | 400 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | unknown | Phase 1 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | unknown | Phase 2 | 108 | Hellenic Society of HematologyOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04375683 | Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL | unknown | Phase 3 | 28 | Zhongda HospitalOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04490707 | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | unknown | Phase 3 | 60 | Ge ZhengOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05293028 | Study of F527 in Patients With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 82 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 23, 2022 | clinicaltrials |
| NCT04112238 | ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma(CNSctDNA) | unknown | — | 75 | Herlev HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT05001386 | In Vitro Drug Sensitivity Testing of Fresh Human Samples(ESAAC) | unknown | N/A | 800 | Hospices Civils de LyonOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05284396 | Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 17, 2022 | clinicaltrials |
| NCT03251352 | TKI Discontinuation in CML Patients of China(TFR_china) | unknown | — | 98 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04823091 | Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies | unknown | Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | unknown | Phase 2 | 35 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05282719 | Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults | unknown | Phase 2 | 33 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2022source: clinicaltrials